GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Schott Pharma AG & CO KGaA (CHIX:1SXPd) » Definitions » Gross Profit

Schott Pharma AG KGaA (CHIX:1SXPD) Gross Profit : €324.2 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Schott Pharma AG KGaA Gross Profit?

Schott Pharma AG KGaA's gross profit for the three months ended in Jun. 2024 was €87.1 Mil. Schott Pharma AG KGaA's gross profit for the trailing twelve months (TTM) ended in Jun. 2024 was €324.2 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Schott Pharma AG KGaA's gross profit for the three months ended in Jun. 2024 was €87.1 Mil. Schott Pharma AG KGaA's Revenue for the three months ended in Jun. 2024 was €253.6 Mil. Therefore, Schott Pharma AG KGaA's Gross Margin % for the quarter that ended in Jun. 2024 was 34.34%.

Schott Pharma AG KGaA had a gross margin of 34.34% for the quarter that ended in Jun. 2024 => Competition eroding margins

During the past 4 years, the highest Gross Margin % of Schott Pharma AG KGaA was 36.10%. The lowest was 33.55%. And the median was 35.05%.


Schott Pharma AG KGaA Gross Profit Historical Data

The historical data trend for Schott Pharma AG KGaA's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Schott Pharma AG KGaA Gross Profit Chart

Schott Pharma AG KGaA Annual Data
Trend Sep20 Sep21 Sep22 Sep23
Gross Profit
196.01 226.17 296.43 316.49

Schott Pharma AG KGaA Quarterly Data
Sep20 Sep21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 74.08 74.30 83.75 79.08 87.08

Competitive Comparison of Schott Pharma AG KGaA's Gross Profit

For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Schott Pharma AG KGaA's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Gross Profit distribution charts can be found below:

* The bar in red indicates where Schott Pharma AG KGaA's Gross Profit falls into.



Schott Pharma AG KGaA Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Schott Pharma AG KGaA's Gross Profit for the fiscal year that ended in Sep. 2023 is calculated as

Gross Profit (A: Sep. 2023 )=Revenue - Cost of Goods Sold
=898.602 - 582.113
=316.5

Schott Pharma AG KGaA's Gross Profit for the quarter that ended in Jun. 2024 is calculated as

Gross Profit (Q: Jun. 2024 )=Revenue - Cost of Goods Sold
=253.587 - 166.505
=87.1

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €324.2 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Schott Pharma AG KGaA's Gross Margin % for the quarter that ended in Jun. 2024 is calculated as

Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=87.1 / 253.587
=34.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Schott Pharma AG KGaA  (CHIX:1SXPd) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Schott Pharma AG KGaA had a gross margin of 34.34% for the quarter that ended in Jun. 2024 => Competition eroding margins


Schott Pharma AG KGaA Gross Profit Related Terms

Thank you for viewing the detailed overview of Schott Pharma AG KGaA's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Schott Pharma AG KGaA Business Description

Comparable Companies
Traded in Other Exchanges
Address
Hattenbergstrasse 10, Mainz, RP, DEU, 55122
Schott Pharma AG & CO KGaA caters to the pharma, biotech and life science industry by providing containment solutions and delivery systems for injectable drugs. Its segments include; Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of the revenue is generated from Drug Containment Solutions segment which includes products like vials, cartridges and ampoules for safe drug containment. Geographically, the company generates revenue from Europe, Middle East, Africa (EMEA), Asia and South Pacific, North America and South America.

Schott Pharma AG KGaA Headlines

No Headlines